{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060452","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.284708+00:00","generated_at":"2026-06-01T23:11:07.525591+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Athira Pharma Q1 2024 net loss $26.3M ($0.69/share); cash $122.1M; LIFT-AD data H2 2024","bullets":["Net loss of $26.3M ($0.69/share) vs $27.8M ($0.73/share) in Q1 2023; operating cash burn $25.8M.","Cash and investments $122.1M as of March 31, 2024, down from $147.4M at year-end 2023.","LIFT-AD Phase 2/3 topline data for fosgonimeton in Alzheimer's expected H2 2024; enrollment complete.","IND submitted for ATH-1105 (ALS); first-in-human study expected to start Q2 2024.","Appointed Javier San Martin, M.D. as Chief Medical Officer in April 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060452","json":"https://secwatch.observer/filing/0000950170-24-060452.json","markdown":"https://secwatch.observer/filing/0000950170-24-060452.md","text":"https://secwatch.observer/filing/0000950170-24-060452.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017024060452/0000950170-24-060452-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017024060452/atha-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:11:07.525591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c662bb4652b64d74c7a424d12987e053f1ff717c","claim":"LeonaBio, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 15, 2024, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000095017024060452/0000950170-24-060452-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}